Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — April 2026

Genmab — April 2026

Planlagt Fastgjort Låst Flyttet Genmab
133 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #9

    Viridian Therapeutics fell another 25% yesterday on Amgen's Tepezza-data... i guess we can see that as a ++ for Tepezza...

    1 Reply Last reply
    0
    • P Offline
      P Offline
      ProinvestorNEWS
      wrote on sidst redigeret af
      #10

      Danske aktier i USA: Novo og Genmab endte lidt over slutniveauet i København https://proinvestor.com/investornyt/1429530/danske-aktier-i-usa-novo-og-genmab-endte-lidt-over-slutniveauet-i-kobenhavn

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #11

        EPCORE
        DLBCL-4 fully recruited https://clinicaltrials.gov/study/NCT06508658?tab=history&a=18&b=19#version-content-panel

        1 Reply Last reply
        0
        • CupcakeC Offline
          CupcakeC Offline
          Cupcake
          wrote on sidst redigeret af
          #12

          "Genmab nærmer sig vigtige begivenheder - Jefferies finder "overdrevne bekymringer" i markedet
          Investorerne forbinder kommende resultater for lymfekræftmidlet Epkinly med en risiko, som den amerikanske storbank Jefferies ikke finder grund til." MedWatch 12:54 Ingen Paywall https://medwatch.dk/brancher/Medicinal___Biotek/article19181589.ece

          1 Reply Last reply
          0
          • B Offline
            B Offline
            bikube
            wrote on sidst redigeret af
            #13

            Se "Ugens grafik" under "nyheder", det er Dara, der vises grafisk virkning.

            1 Reply Last reply
            0
            • CupcakeC Offline
              CupcakeC Offline
              Cupcake
              wrote on sidst redigeret af
              #14

              8/4 14:43 - Paywall kører igen....

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #15

                The Role of LGR5 in Epithelial Cancer https://www.hematologyandoncology.net/archives/march-april-2026/the-role-of-lgr5-in-epithelial-cancer/

                1 Reply Last reply
                0
                • G Offline
                  G Offline
                  gentogen
                  wrote on sidst redigeret af
                  #16

                  Thanks EL. Very interesting. Also thanks for the previous various good news.

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #17

                    unfortunately not that much news going around at the moment... JnJ earnings next week, and we may get some ASCO abstract titles towards the end of the month...

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #18

                      Genmab: Multiple Binaries Could Alter The Thesis https://seekingalpha.com/article/4889570-genmab-multiple-binaries-could-alter-thesis

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #19

                        Lesions in Radiated/Non-Radiated Fields Achieve Similar Responses with Tisotumab Vedotin in Cervical Cancer https://www.cancernetwork.com/view/lesions-in-radiated-non-radiated-fields-achieve-similar-responses-with-tisotumab-vedotin-in-cervical-cancer?utm_content=375412874&utm_medium=social&utm_source=twitter&hss_channel=tw-22195223

                        1 Reply Last reply
                        0
                        • P Offline
                          P Offline
                          ProinvestorNEWS
                          wrote on sidst redigeret af
                          #20

                          Første kvartal: Viser danske selskaber sig kriseturbulente på et uroligt bagtæppe?
                          De danske regnskaber for C25-selskaberne starter i denne uge. Danske aktier har været
                          under kurspres de seneste kvartaler og år. Viser resultaterne sig nu mere økonomisk
                          resistente end den negative aktiekursudvikling lader forstå? https://proinvestor.com/boards/131937

                          1 Reply Last reply
                          0
                          • Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktør
                            wrote on sidst redigeret af
                            #21

                            Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer https://proinvestor.com/investornyt/1431279/genmab-presents-the-safety-and-tolerability-of-rinatabart-sesutecan-rina-s-in-combination-with-bevacizumab-in-advanced-ovarian-cancer

                            1 Reply Last reply
                            0
                            • SolsenS Offline
                              SolsenS Offline
                              Solsen
                              wrote on sidst redigeret af
                              #22

                              Så mangler vi blot effekt data….

                              1 Reply Last reply
                              0
                              • P Offline
                                P Offline
                                peter12
                                wrote on sidst redigeret af
                                #23

                                Fandt denne på X, det virker ret overbevisende ?https://www.oncnursingnews.com/view/how-does-rina-s-work-in-patients-with-pretreated-endometrial-cancer-

                                1 Reply Last reply
                                0
                                • P Offline
                                  P Offline
                                  peter12
                                  wrote on sidst redigeret af
                                  #24

                                  Ok det var endometrial cancer sorry 😉

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #25

                                    Tisotumab Vedotin With Carboplatin/Pembrolizumab ± Bevacizumab Shows Activity in Cervical Cancer https://www.onclive.com/view/tisotumab-vedotin-with-carboplatin-pembrolizumab-bevacizumab-shows-activity-in-cervical-cancer

                                    1 Reply Last reply
                                    0
                                    • P Offline
                                      P Offline
                                      ProinvestorNEWS
                                      wrote on sidst redigeret af
                                      #26

                                      Genmab (+0,3%, 1795,50) kan få opmærksomhed, når den amerikanske samarbejdspartner og medicinalkoncern Johnson & Johnson kommer med regnskab for første kvartal. Af særlig dansk interesse er information om lægemidlet Darzalex. Genmab modtager royalties for salget af knoglemarvskræftmidlet Darzalex, som markedsføres af Johnson & Johnson.

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #27

                                        Jyske Bank upgrades Genmab to Buy from Hold, sets price target at DKK 2,300 - BN
                                        Published on 04/14/2026

                                        1 Reply Last reply
                                        0
                                        • P Offline
                                          P Offline
                                          ProinvestorNEWS
                                          wrote on sidst redigeret af
                                          #28

                                          Jyske Bank opgraderer Genmab til Køb fra Hold, siger en længere periode med modvind for virksomheden repræsenterer en god købsmulighed.

                                          De kommende resultater forventes ikke at bringe nogen større nyheder. På den anden side er aktien faldet næsten 20% siden dens seneste top i januar efter makroøkonomiske modvinde og skuffende nyheder om Epkinly.

                                          Med udsigten til en begivenhedsrig anden halvdel af året er det derfor et godt tidspunkt at gå ind i aktien, siger Jyske Bank.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper